Preschool Supplement to Clonidine in ADHD (Kiddie-CAT)
Launched by UNIVERSITY OF CINCINNATI · Dec 21, 2006
Trial Information
Current as of August 27, 2025
Completed
Keywords
ClinConnect Summary
Attention deficit hyperactivity disorder (ADHD) is a disease characterized by one or more symptoms of hyperactivity, impulsivity, or inattention that interfere with school, home, work, or social settings. ADHD does not have clear physical signs that can be seen in an x-ray or a lab test. The disorder only can be identified by looking for certain behaviors, which vary from person to person.
This trial will compare the benefits and side effects of two medications--clonidine and methylphenidate (MPH)--used alone or in combination to treat ADHD in children. MPH is approved by the Food and Drug...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Child with ADHD
- • Child ages 4 through 6
- • Child attending a structured preschool or daycare
- Exclusion Criteria:
- • Presence of a tic disorder of any kind or a known active heart disease for which it would be unsafe to use the study drugs
- • Presence of pervasive developmental disorder, autism, mental retardation, or serious psychiatric illness
- • Child not attending a structured preschool or daycare
About University Of Cincinnati
The University of Cincinnati is a leading research institution dedicated to advancing healthcare through innovative clinical trials and studies. With a robust focus on translational research, the university fosters a collaborative environment that integrates cutting-edge science with clinical practice. Its diverse team of experts, equipped with state-of-the-art facilities, is committed to exploring new therapeutic interventions aimed at improving patient outcomes. The University of Cincinnati actively engages in partnerships with industry and academia to drive forward-thinking solutions in medicine, ensuring that research findings are effectively translated into real-world applications.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rochester, New York, United States
Cincinnati, Ohio, United States
Pittsburgh, Pennsylvania, United States
Patients applied
Trial Officials
Floyd Randy Sallee, MD/PhD
Principal Investigator
University of Cincinnati
Oscar Bukstein, MD
Principal Investigator
Western Psychiatric Institute and Clinic
Donna Palumbo, PhD
Principal Investigator
University of Rochester
William Pelham, PhD
Principal Investigator
SUNY Buffalo
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials